PortalPublikationenDifferences in histopathological and biochemical outcomes in...

Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer.

Standard

Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer. / Isbarn, Hendrik; Karakiewicz, Pierre I; Ahyai, Sascha A; Chun, Felix; Jeldres, Claudio; Haese, Alexander; Heinzer, Hans; Zacharias, Mario; Heuer, Roman; Eichelberg, Christian; Steuber, Thomas; Budäus, Lars; Köllermann, Jens; Salomon, Georg; Schlomm, Thorsten; Perrotte, Paul; Fisch, Margit; Huland, Hartwig; Graefen, Markus.

in: BJU INT, 2009.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Isbarn, H, Karakiewicz, PI, Ahyai, SA, Chun, F, Jeldres, C, Haese, A, Heinzer, H, Zacharias, M, Heuer, R, Eichelberg, C, Steuber, T, Budäus, L, Köllermann, J, Salomon, G, Schlomm, T, Perrotte, P, Fisch, M, Huland, H & Graefen, M 2009, 'Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer.', BJU INT. <http://www.ncbi.nlm.nih.gov/pubmed/19751264?dopt=Citation>

APA

Isbarn, H., Karakiewicz, P. I., Ahyai, S. A., Chun, F., Jeldres, C., Haese, A., Heinzer, H., Zacharias, M., Heuer, R., Eichelberg, C., Steuber, T., Budäus, L., Köllermann, J., Salomon, G., Schlomm, T., Perrotte, P., Fisch, M., Huland, H., & Graefen, M. (2009). Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer. BJU INT. http://www.ncbi.nlm.nih.gov/pubmed/19751264?dopt=Citation

Vancouver

Isbarn H, Karakiewicz PI, Ahyai SA, Chun F, Jeldres C, Haese A et al. Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer. BJU INT. 2009.

Bibtex

@article{8f99402802a64aa38863d5981face41e,
title = "Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer.",
abstract = "OBJECTIVE To test whether the number or percentage of positive biopsy cores can be used to discriminate between patients with prostate cancer of a favourable and less favourable Gleason score (GS) /=3) were stratified into low- vs high-risk groups. Subsequently, we stratified patients according to the GS and the percentage of positive biopsy cores (/=50%). The pathological stage and the 5-year biochemical recurrence (BCR)-free survival rates were examined in univariable and multivariable models. RESULTS Based on the number of positive cores, the rate of extraprostatic disease was 11.7% and 23.3%, respectively, in the low-and high-risk GS",
author = "Hendrik Isbarn and Karakiewicz, {Pierre I} and Ahyai, {Sascha A} and Felix Chun and Claudio Jeldres and Alexander Haese and Hans Heinzer and Mario Zacharias and Roman Heuer and Christian Eichelberg and Thomas Steuber and Lars Bud{\"a}us and Jens K{\"o}llermann and Georg Salomon and Thorsten Schlomm and Paul Perrotte and Margit Fisch and Hartwig Huland and Markus Graefen",
year = "2009",
language = "Deutsch",
journal = "BJU INT",
issn = "1464-4096",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Differences in histopathological and biochemical outcomes in patients with low Gleason score prostate cancer.

AU - Isbarn, Hendrik

AU - Karakiewicz, Pierre I

AU - Ahyai, Sascha A

AU - Chun, Felix

AU - Jeldres, Claudio

AU - Haese, Alexander

AU - Heinzer, Hans

AU - Zacharias, Mario

AU - Heuer, Roman

AU - Eichelberg, Christian

AU - Steuber, Thomas

AU - Budäus, Lars

AU - Köllermann, Jens

AU - Salomon, Georg

AU - Schlomm, Thorsten

AU - Perrotte, Paul

AU - Fisch, Margit

AU - Huland, Hartwig

AU - Graefen, Markus

PY - 2009

Y1 - 2009

N2 - OBJECTIVE To test whether the number or percentage of positive biopsy cores can be used to discriminate between patients with prostate cancer of a favourable and less favourable Gleason score (GS) /=3) were stratified into low- vs high-risk groups. Subsequently, we stratified patients according to the GS and the percentage of positive biopsy cores (/=50%). The pathological stage and the 5-year biochemical recurrence (BCR)-free survival rates were examined in univariable and multivariable models. RESULTS Based on the number of positive cores, the rate of extraprostatic disease was 11.7% and 23.3%, respectively, in the low-and high-risk GS

AB - OBJECTIVE To test whether the number or percentage of positive biopsy cores can be used to discriminate between patients with prostate cancer of a favourable and less favourable Gleason score (GS) /=3) were stratified into low- vs high-risk groups. Subsequently, we stratified patients according to the GS and the percentage of positive biopsy cores (/=50%). The pathological stage and the 5-year biochemical recurrence (BCR)-free survival rates were examined in univariable and multivariable models. RESULTS Based on the number of positive cores, the rate of extraprostatic disease was 11.7% and 23.3%, respectively, in the low-and high-risk GS

M3 - SCORING: Zeitschriftenaufsatz

JO - BJU INT

JF - BJU INT

SN - 1464-4096

ER -